These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35803246)

  • 21. The RPL/RPS gene signature of melanoma CTCs associates with brain metastasis.
    Bowley TY; Lagutina IV; Francis C; Sivakumar S; Selwyn RG; Taylor E; Guo Y; Fahy BN; Tawfik B; Marchetti D
    Cancer Res Commun; 2022 Nov; 2(11):1436-1448. PubMed ID: 36407834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the systemic treatment of melanoma brain metastases.
    Glitza Oliva IC; Schvartsman G; Tawbi H
    Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic and gene expression features of metastatic melanomas to the brain.
    Hamilton R; Krauze M; Romkes M; Omolo B; Konstantinopoulos P; Reinhart T; Harasymczuk M; Wang Y; Lin Y; Ferrone S; Whiteside T; Bortoluzzi S; Werley J; Nukui T; Fallert-Junecko B; Kondziolka D; Ibrahim J; Becker D; Kirkwood J; Moschos S
    Cancer; 2013 Aug; 119(15):2737-46. PubMed ID: 23695963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
    Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
    Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
    Weiss SA; Zito C; Tran T; Heishima K; Neumeister V; McGuire J; Adeniran A; Kluger H; Jilaveanu LB
    J Neurooncol; 2021 Mar; 152(1):15-25. PubMed ID: 32974852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.
    Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
    Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq.
    Carmona SJ; Siddiqui I; Bilous M; Held W; Gfeller D
    Oncoimmunology; 2020; 9(1):1737369. PubMed ID: 32313720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
    Stejerean-Todoran I; Gimotty PA; Watters A; Brafford P; Krepler C; Godok T; Li H; Bonilla Del Rio Z; Zieseniss A; Katschinski DM; Sertel SM; Rizzoli SO; Garman B; Nathanson KL; Xu X; Chen Q; Oswald JH; Lotem M; Mills GB; Davies MA; Schön MP; Bogeski I; Herlyn M; Vultur A
    Neuro Oncol; 2023 Apr; 25(4):674-686. PubMed ID: 36054930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the treatment-naive immune microenvironment in melanoma with
    Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases.
    Fischer GM; Guerrieri RA; Hu Q; Joon AY; Kumar S; Haydu LE; McQuade JL; Vashisht Gopal YN; Knighton B; Deng W; Hudgens CW; Lazar AJ; Tetzlaff MT; Davies MA
    Neurooncol Adv; 2021; 3(1):vdaa177. PubMed ID: 33575655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
    Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
    Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
    Marzese DM; Scolyer RA; Huynh JL; Huang SK; Hirose H; Chong KK; Kiyohara E; Wang J; Kawas NP; Donovan NC; Hata K; Wilmott JS; Murali R; Buckland ME; Shivalingam B; Thompson JF; Morton DL; Kelly DF; Hoon DS
    Hum Mol Genet; 2014 Jan; 23(1):226-38. PubMed ID: 24014427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
    In GK; Ribeiro JR; Yin J; Xiu J; Bustos MA; Ito F; Chow F; Zada G; Hwang L; Salama AKS; Park SJ; Moser JC; Darabi S; Domingo-Musibay E; Ascierto ML; Margolin K; Lutzky J; Gibney GT; Atkins MB; Izar B; Hoon DSB; VanderWalde AM
    NPJ Precis Oncol; 2023 Nov; 7(1):120. PubMed ID: 37964004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
    Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
    Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
    Phadke M; Ozgun A; Eroglu Z; Smalley KSM
    Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
    Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
    Front Immunol; 2020; 11():120. PubMed ID: 32117271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.